Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Formycon’s Pembrolizumab Biosimilar Enters Ph III Clinical Trial

Jul 30, 2024

Five days after Bio-Thera announced the start of its integrated Phase I/III trials for BAT3306 (pembrolizumab), on 30 July 2024, Formycon announced enrolment of the first patient in its Phase III trial for FYB206 (pembrolizumab), biosimilar to MSD’s Keytruda®.  The “Lotus” trial will compare the safety and efficacy of FYB206 with Keytruda® in patients with non-small cell lung cancer (NSCLC) in Eastern Europe and Southeast Asia.

Formycon commenced a Phase I trial for FY206 in malignant melanoma patients in June 2024.

FYB206 and BAT3306 join a raft of other pembrolizumab biosimilars in clinical trials including Amgen’s ABP 234 (Ph 3 study in nsNSCLC initiated May 2024), Samsung Bioepis’ SB27 (Ph 3 study for metastatic nsNSCLC commenced April 2024) and Sandoz’s GME751 (Ph 1 and 3 clinical trials commenced in April/May 2024).  In March 2024, Korea Biomedical Review reported that Rophibio entered into an agreement with US biotech Avantor in relation to the development of a pembrolizumab biosimilar.  Xbrane and Celltrion have also each previously announced joint pembrolizumab biosimilar development.